摩根大通发布研报称，科伦博泰生物（06990）近日股价表现强劲，相信主要是由于靶向人滋养细胞表面抗原2（TROP2）的抗体偶联药物（ADC）芦康沙妥珠单抗（sac-TMT），在中国进行的OptiTROP-Lung06三期临床试验达到主要终点，是首次有ADC+PD-1联合疗法在这个阶段展示出显著优于Keytruda+化疗的疗效。该行将公司目标价由535港元上调至648港元，续予“增持”评级。
此外，国家药监局已对sac-TMT用于TNBC的补充新药申请授予优先审评资格，进一步降低了监管与执行风险。小摩表示，随着科伦博泰多项在中国进行的注册性研究取得积极成果，以及该资产在多个瘤种中的验证增加，临床风险已大幅降低。
责任编辑：卢昱君
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.